Are there tests (e.g., in vitro testing on tissue), or biomarkers that could help influence the decision? Or other...
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Tests and Biomarkers That Could Guide Josh's Treatment Decisions
Based on Josh's clinical summary, there are several important testing and biomarker considerations that could help inform his next steps:
Available Tissue Resources
The document specifically notes that tissue from Josh's recent splenectomy (September 2025) is available for molecular testing. This is a significant resource that hasn't been fully utilized yet. The summary recommends "molecular profiling of available tissue samples to guide treatment decisions."
Current Biomarker Information
The document confirms Josh has BCL-6 pathway involvement (which is why he was enrolled in the BCL-6 degrader trial). However, the summary notes an important gap:
"Specific genomic mutations, BRCA status, IHC results, and methylation data not provided in available records"
This means comprehensive molecular testing could reveal:
- Additional genetic mutations that might respond to targeted therapies
- Protein expression patterns (immunohistochemistry/IHC) that could identify new treatment targets
- Epigenetic changes that might be actionable
Key Consideration from the Document
The upcoming biopsy scheduled for [date removed] is critical. The summary recommends coordinating "tissue allocation for research testing" — meaning Josh should discuss with his care team how to maximize what can be learned from this biopsy.
Important Next Step
According to NCCN Guidelines for Non-Hodgkin's Lymphomas, comprehensive molecular profiling is recommended for relapsed/refractory disease to identify potential treatment targets. Josh should ask his oncology team specifically about:
- What molecular testing will be performed on the November biopsy
- How results might open new treatment pathways beyond the recommended allogeneic transplant
Would you like me to discuss what specific tests are typically recommended for relapsed follicular lymphoma?
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Related Services
Services that may help with diagnosis for cancer patients
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history:
Related Questions
Er+ oligomet breast cancer. Have been 5aking ribocyclib for 14 months. Because of my low neutrophils the dose was...
I appreciate you sharing these details about your treatment journey. Let me help you understand what's happening and what questions to bring to your o
What signs of progression should I watch for
Based on NCCN Guidelines for Myeloproliferative Neoplasms, here are the key warning signs you should monitor and report to your oncologist: Blood Co
What questions should I ask my oncologist at my next appointment
I'd love to help you prepare for your appointment! To give you the most relevant questions, it would help to know a bit more about your situation: 1.
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
Thank you for the follow-up. I want to address something important that emerged from your medical profile: Your actual diagnosis is a fibroblastic/my
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
I appreciate your question about these specific mutations. However, I want to first clarify something important about your medical profile: Your Situ